EYLEA HD® and EYLEA® remained the U.S. anti-VEGF category leader in 2024; aggregate U.S. net product sales were $6 billion for full-year 2024, up 1% based on preliminary (unaudited) results EYLEA HD ...

Tafasitamab increased progression free survival by about 9 months when compared to placebo, according to recent study data.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

In the Mithic-FL1 trial, patients with newly diagnosed high-burden follicular lymphoma (FL) demonstrated complete response (CR) rates of 80% and manageable adverse events with outpatient ...

Liso-cel, a CD19-directed chimeric antigen receptor T-cell product, and mosunetuzumab, a CD20/CD3 bispecific antibody, are used to treat patients with relapsed/refractory follicular lymphoma.

When cancer originates in the lymph nodes of the lymphatic system, it is known as lymphoma. Many types of lymphoma exist, defined by their origin, location in the body, and cell characteristics.

The age and pathological type of patients with uterine lymphoma are related, and diffuse large B-cell lymphoma is most common in women aged 35 to 45; Follicular lymphoma is more likely to occur ...

Source: Science Source Images Could results from the inMIND, EA4151, TRIANGLE, and ENRICH trials change the treatment of patients with mantle cell lymphoma and follicular lymphoma? Research ...